1 bioresearch monitoring and in vitro diagnostics sybil wellstood, ph.d. office of compliance...
TRANSCRIPT
1
BIORESEARCH MONITORING AND IN VITRO DIAGNOSTICS
SYBIL WELLSTOOD, PH.D.OFFICE OF COMPLIANCE
DIVISION OF BIORESEARCH MONITORING
2
OBJECTIVES
PROVIDE OVERVIEW OF THE CDRH BIORESEARCH MONITORING PROGRAM (BIMO)
-What it is -What we do -Who we are
DISCUSS HOW THE BIMO PROGRAM APPLIES TO IN VITRO DIAGNOSTIC (IVD) STUDIES CONDUCTED UNDER 510(K) PREMARKET NOTIFICATIONS
3
BIORESEARCH MONITORING PROGRAM (BIMO)
COMPREHENSIVE AGENCY-WIDE COMPLIANCE PROGRAM TO MONITOR FDA-REGULATED RESEARCH
-Inspections -Data Audits
4
RESEARCH SUBJECT TO FDA’s BIMO PROGRAM
Research Conducted for Submission to FDA
to Support Applications for Research or
Marketing Permits: Clinical Studies-Humans (Safety & Effectiveness) PreClinical, Nonclinical Laboratory Studies-
Analytical tests, Animals (Safety)
5
BIMO MISSION VERIFY QUALITY AND INTEGRITY OF
DATA/INFORMATION SUBMITTED IN RESEARCH OR MARKETING APPLICATIONS INCLUDING 510(k)s.
PROTECT THE RIGHTS AND WELFARE OF HUMAN RESEARCH SUBJECTS PARTICIPATING IN FDA-REGULATED STUDIES.
6
WHO WE ARE OFFICE OF COMPLIANCE DIVISION OF BIORESEARCH MONITORING Program Enforcement Branch I Program Enforcement Branch II IVDs Preclinical studies
IDE
Division of Bioresearch Monitoring
Food and Drug Administration
Center for Devices and Radiological Health
Office of Compliance
A ssur ing r esear ch in tegr i ty thr oughhuman subject pr otection
& data in tegr i ty audi ts
Investigational device ad
Complaint
Integrity issue
510(k)
PDP
PMA
7
WHAT WE DO
DEVELOP AND ISSUE INSPECTION ASSIGNMENTS TO FDA FIELD OFFICES
EVALUATE AND CLASSIFY ESTABLISHMENT INSPECTION REPORTS (EIRS)
INITIATE FOLLOW-UP REGULATORY ACTIONS AND CORRESPONDENCE
8
WHO WE INSPECT
SPONSORS-INCLUDING IVD MANUFACTURERS MONITORS, CLINICAL RESEARCH
ORGANIZATIONS CLINICAL INVESTIGATORS INSTITUTIONAL REVIEW BOARDS NONCLINICAL LABORATORIES325 + TOTAL BIMO INSPECTIONS IN FY 2003
9
21 CFR 812.2 (c)(3)
EXEMPTS DIAGNOSTICS SUBMITTED AS510(K)S FROM REQUIRING ANINVESTIGATIONAL DEVICE EXEMPTION (IDE) TO CONDUCT STUDIES.
10
FDA EXPECTATIONS FOR IDE EXEMPT STUDIES
MUST FOLLOW GOOD RESEARCH PRACTICES.
SUBMIT VALID SCIENTIFIC DATA TO DEMONSTRATE SAFETY AND EFFECTIVENESS.
MEET REQUIREMENTS IN 21 CFR PARTS 50 AND 56 FOR HUMAN SUBJECT PROTECTION WHEN APPLICABLE.
LABEL PRODUCT “FOR RESEARCH/INVESTIGATIONAL USE ONLY.”
11
HUMAN SUBJECT PROTECTION 21 CFR PARTS 50 & 56
APPLY TO ALL STUDIES SUPPORTING RESEARCH OR MARKETING PERMITS FOR FDA-REGULATED PRODUCTS INVOLVING HUMAN SUBJECTS
OR THEIR SPECIMENS
12
HUMAN SUBJECT 21 CFR 812.3(p)
A HUMAN WHO PARTICIPATES IN AN INVESTIGATION EITHER AS AN INDIVIDUAL ON WHOM, OR ON WHOSE SPECIMEN, AN INVESTIGATIONAL DEVICE IS USED OR USED AS A CONTROL.
13
21 CFR PARTS 50/56 REQUIREMENTS
IRB REVIEW/APPROVAL OF STUDIES INFORMED CONSENT -Must contain all required elements
in 21 CFR 50.25.
14
BIMO IVD 510(k) INSPECTIONS
REQUESTED BY OIVDS- DATA APPEAR SUSPICIOUS,
FRAUDULANT, UNREALISTIC INVESTIGATE VALID COMPLAINTS/ WHISLEBLOWER ALLEGATIONS FOLLOW UP ON PREVIOUS
INSPECTIONS INVOLVING SERIOUS NONCOMPLIANCE ISSUES
f
15
BIMO IVD 510(K) INSPECTIONS Directed-Submission Based
Monitor compliance (Human subject protection)
Assess data quality Verify accuracy of data submitted in
application
For Cause-Problem or Complaint Based focus on special issues/problems compliance follow-up often include interviews May include sworn affidavits
16
BIMO INSPECTION PROCESS
Telephone call-short notice FDA investigator shows credentials Investigator issues a written notice
of inspection to most responsible person (FDA-482)
Investigator discusses the general nature of the inspection
17
During the inspection…..
Facilities tour. Ongoing discussion of inspectional
proceedings and findings; no surprises at conclusion.
Collect records to substantiate observations/facts.
May collect sworn affidavits.
18
Concluding the inspection…
Summary discussion of findings. Investigator may issue Form FDA-
483-a written report of the objectionable conditions observed reflecting deviations from regulations.
Deviations from guidelines do not appear on the Form FDA-483, but may be included in the discussion.
19
FDA 483s and responding…
If issued, respond verbally during the final discussion (investigator will include response in EIR).
Send a written response to District Office and Center contact.
You may opt to do both (most do today).
20
RESPONDING TO 483 ITEMS Explain any special circumstances
regarding observations.
Describe specific actions taken or planned that will correct and prevent future deviations.
21
ESTABLISHMENT INSPECTION REPORT (EIR)
Prepared by the Investigator or team of Investigators performing the inspection following every inspection.
-details inspection and findings. -includes exhibits to document findings. -provides a preliminary classification. EIRs for BIMO inspections sent to assigning
Centers for review and final classification. Assigning Centers issue post-inspectional
correspondence and initiate follow up actions. Only available by FOIA.
22
EIR INSPECTION CLASSIFICATIONS
NAI – NO ACTION INDICATED No objectionable conditions or practices.
VAI – VOLUNTARY ACTION INDICATED Objectionable conditions; not at threshold to take
or recommend administrative or regulatory action. OAI – OFFICIAL ACTION INDICATED Serious or numerous objectionable conditions
found. Regulatory actions recommended.
23
POST INSPECTIONAL REGULATORY ACTIONS
Correspondence-Warning Letter
Re-inspection Informal conference 3rd party validation Study/data rejection Disqualification (CIs)
Injunction Revoke marketing
permit Terminate research
permit Prosecution Civil Penalties Application integrity
policy(AIP)invoked
24
APPLICATION INTEGRITY POLICY (AIP) ADMINISTRATIVE ACTION
USED WHEN THERE IS EVIDENCE THAT SUBMISSIONS CONTAIN FALSE, MISLEADING, OR UNRELIABLE INFORMATION.
PATTERN OR PRACTICE OF WRONGFUL ACTS.
25
AIP CONSEQUENCES
STOPS REVIEW OF ALL SPONSOR’S APPLICATIONS CURRENTLY UNDER REVIEW.
STOPS REVIEW OF ANY NEW SUBMISSIONS.
26
FDA’s ACTIONS
Issue AIP letter to applicant
Suspends review of in-house and future applications
27
APPLICANT’S RESPONSIBILITIES
Conduct internal review independent outside consultant
Submit corrective action plan (CAP)
28
FDA FOLLOW UP
Review CAP
Inspect to verify internal audit completed and CAP implemented
Headquarters reviews EIR
Letter to applicant of findings
--Remove AIP; continue review
29
FDA FOLLOW UP
REQUEST VOLUNTARY WITHDRAWAL
OF PENDING APPLICATIONS.
RESCIND CLEARANCE/APPROVAL MARKETED PRODUCTS; REMOVE FROM MARKET.
30
SUMMARY The FDA BIMO programs audit and inspect
clinical research and research data to assure: -- the reliability/integrity of research
data submitted in marketing/research
permits. --assures that human subject protections are
in place. Oversight includes studies for diagnostics
submitted as 510(k)s.
31
32
DIVISION OF BIORESEARCH MONITORING
Internet Home Page Address:
http://www.fda.gov/cdrh/ comp/bimo.html